Trial Profile
A Study of K-333 (peretinoin) in Patients with Complete Cure of Hepatitis B Virus (HBV)-Positive Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Peretinoin (Primary)
- Indications Hepatitis B; Liver cancer
- Focus Therapeutic Use
- Sponsors Kowa Pharmaceutical
- 10 Apr 2018 Status changed from active, no longer recruiting to completed.
- 13 Jun 2016 New trial record